Celgene Gets FDA OK to Expand Lymphoma Drug

Celgene Corp said it received expedited U.S. regulatory approval to expand the use of its Istodax drug in the treatment of cancers.

The biotechnology company said the U.S. Food and Drug Administration granted an accelerated approval for its application to use Istodax to treat peripheral T-cell lymphoma in patients who have received at least one prior therapy.

Istodax is already approved in the United States for treating cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy.

The agency was originally scheduled to make a ruling on the application, which was filed in January, on Friday.